Results 101 to 110 of about 40,229 (203)

Real-world efficacy and safety of cefepime for pediatric community-acquired pneumonia: a propensity score-matched study

open access: yesFrontiers in Cellular and Infection Microbiology
ObjectiveThis study aimed to evaluate the real-world clinical efficacy and safety of cefepime in treating pediatric community-acquired pneumonia (CAP), comparing it with other broad-spectrum antibiotics, including cefoperazone-sulbactam and meropenem ...
Changxin Liu   +6 more
doaj   +1 more source

Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation

open access: yes
Introduction: Cefepime/enmetazobactam is a novel β-lactam/β-lactamase inhibitor (BL-BLI) combination with broad Gram-positive and -negative activity. Cefepime is relatively resistant to hydrolysis by AmpC, and enmetazobactam inhibits all Ambler Class A ...
Dubey, Vineet   +2 more
core   +1 more source

FIC values of Ampicillin/sulbactam plus Cefepime combination.

open access: yes, 2017
FIC values of Ampicillin/sulbactam plus Cefepime combination.
Mona M. Abdelkader (3753058)   +3 more
core   +1 more source

Molecular epidemiology and β-lactam resistance mechanisms of Enterobacter cloacae complex isolates obtained from bloodstream infections, Kyoto, Japan

open access: yesMicrobiology Spectrum
The Enterobacter cloacae complex (ECC) comprises multiple species that require genomic analysis for precise identification. They produce inducible AmpC β-lactamase and may carry acquired β-lactamases, which are responsible for cefotaxime and cefepime ...
Akihiko Matsuo   +5 more
doaj   +1 more source

Cefepime Resistance and Associated Risk Factors among <i>Escherichia coli </i>Strains Isolated from Clinical Specimens

open access: yes, 2011
Cefepime is active against bacteria producing chromosomally and plasmid-mediated extended broad-spectrum β-lactamase enzymes. The aim of this study was to evaluate risk factors for acquisition of cefepime resistance in <i>Escherichia coli </i>
Parisa Norabadi   +2 more
core   +1 more source

Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit

open access: yesBrazilian Journal of Infectious Diseases
Antibiotic restriction can be useful in maintaining bacterial susceptibility. The objective of this study was verify if restriction of cefepime, the most frequently used cephalosporin in our neonatal intensive care unit (NICU), would ameliorate broad ...
Orlei Ribeiro de Araujo   +7 more
doaj   +1 more source

Post-Antibiotic Effect of Levofloxacin and Tobramycin Alone or in Combination with Cefepime against Pseudomonas aeruginosa

open access: yes, 2009
Background: Levofloxacin and tobramycin, alone and in combination with cefepime, were investigated for their in vitro activities and post-antibiotic effects (PAEs) on Pseudomonas aeruginosa. Methods: The in vitro activities of tobramycin and levofloxacin
Ozbek, Berna   +3 more
core   +1 more source

Rapid detection of cefepime-taniborbactam susceptibility/resistance in Enterobacterales

open access: yes
Objective: Metallo-β-lactamase-producing Enterobacterales is widely distributed and confers resistance to all β-lactams, including carbapenems. Recently, a cefepime-taniborbactam combination has been developed that aims to provide a treatment option ...
Le Terrier, Christophe   +4 more
core   +1 more source

Farmacocinética de Cefepime en pacientes con neoplasias hematológicas y neutropenia febril post-quimioterapia en el Instituto Nacional de Cancerología, empresa social del estado, Bogotá [PDF]

open access: yes, 2015
Este estudio abierto, no aleatorizado, observacional, descriptivo, prospectivo evalúa los parámetros PK de cefepime en pacientes con neoplasias hematológicas y NFPQ en el INC, consta de dos fases: La primera, 15 pacientes con neoplasia hematológica, sin ...
Álvarez Rodríguez, José Camilo
core  

The safety of cefepime in the treatment of infection

open access: yes, 2008
Cefepime is a fourth-generation cephalosporin usually reserved for treating severe nosocomial pneumonia, as well as empirical treatment of febrile neutropenia, uncomplicated and complicated urinary tract infections, uncomplicated skin and skin structure ...
E. De Vecchi, L. Drago
core   +1 more source

Home - About - Disclaimer - Privacy